KRAS and neoplasm: Although both KRAS 300/145 and KRAS 300/73 DII decreased with tumour progression (13- and 30-fold decrease, respectively), KRAS 300/145 DII remained more elevated than 300/73 DII (for instance the mouse #16 DII was 0.13 for the KRAS 300/145 ratio and 0.02 for the KRAS 300/73 ratio).